Pharmaceutical - Financial, Pfizer

Filter

Current filters:

FinancialPfizer

Popular Filters

1 to 25 of 34 results

Despite patent cliffs, pharma market shows signs of stability

19-11-2014

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies…

Biogen IdecBoehringer IngelheimFinancialJohnson & JohnsonPatentsPfizerPharmaceutical

Pfizer beats sales and earnings forecast for the third quarter

Pfizer beats sales and earnings forecast for the third quarter

28-10-2014

US pharma giant Pfizer has beaten the forecasts for both its sales and its earnings for the third quarter…

FinancialLyricaPfizerPharmaceuticalUSAViagra

Earnings at Pfizer tank but still just beat expectations

Earnings at Pfizer tank but still just beat expectations

29-07-2014

Taking the brunt of generic competition to former blockbuster drugs, US pharma giant Pfizer posted a…

FinancialPfizerPharmaceuticalUSA

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

Pfizer shares gain despite lower sales and profits

Pfizer shares gain despite lower sales and profits

29-01-2014

US pharma giant Pfizer reported fourth-quarter and full-year 2013 financial results that beat consensus…

FinancialPfizerPharmaceutical

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

New Zealand views addition of rotavirus, varicella vaccines to national immunization schedule

07-11-2013

A vaccine for the gastric infection rotavirus and protection from varicella for the most vulnerable people…

FinancialHealthcareNew ZealandPfizerPharmaceuticalPrevenarVaccines

Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales

29-10-2013

Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Repligen gets first milestone under SMA deal with Pfizer

05-09-2013

USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

TVM Life Science Ventures invests in Ixchelsis

09-08-2013

Canada-based TVM Life Science Ventures VII has announced the fund's second investment, with Ixchelsis…

Eli LillyFinancialIX-01IxchelsisMen's HealthPfizerPharmaceuticalResearch

Pfizer legacy company agrees near half billion dollar settlement with DoJ

31-07-2013

Wyeth Pharmaceuticals, a US pharma rival acquired by US behemoth Pfizer (NYSE:PFE) in 2009, has agreed…

FinancialImmunologicalsLegalMarkets & MarketingNorth AmericaPfizerPharmaceuticalRapamuneWyeth

Pfizer beats forecasts, as 2nd-qtr earnings rocket on asset sale

30-07-2013

Second-quarter 2013 net income at US pharma behemoth Pfizer (NYSE: PFE) leapt more than four-fold, helped…

FinancialPfizerPharmaceutical

Pfizer to split-off remaining 80% interest in Zoetis

22-05-2013

Zoetis Inc (Nasdaq: ZTS), the animal health business of which US pharma behemoth Pfizer (NYSE: PFE) spun…

FinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer 1st-qtr 2013 disappoints, despite near 54% leap in net income

01-05-2013

US drugs behemoth Pfizer's (NYSE: PFE) shares fell 4.5% to $29.07 by close of trading in New York yesterday…

FinancialPfizerPharmaceutical

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co

04-02-2013

Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer's 4th-qtr beats forecasts, benefitting from Nutrition business sale

30-01-2013

Global drugs behemoth Pfizer (NYSE: PFE) reported better-than-expected fourth-quarter 2012 financial…

FinancialPfizerPharmaceutical

Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal

20-01-2013

Pfizer (NYSE: PFE), the world's largest drugmaker by sales, which has previously said it is spinning…

BGI-ShenzhenBiotechnologyComplete GenomicsFinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug

02-11-2012

US pharma behemoth Pfizer (NYSE: PFE) saw it shares fall 1.1% to $24.59 in morning trading yesterday,…

EuropeFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

1 to 25 of 34 results

Back to top